ArticleMolecular biomedicine2026
Lactate-driven pyrimidine synthesis promotes ferroptosis resistance in hepatocellular carcinoma.
Article in Molecular biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Hepatocellular carcinoma (HCC) remains highly lethal, and emerging therapeutic strategies increasingly focus on harnessing ferroptosis to overcome treatment resistance. However, ferroptosis resistance has emerged as a major barrier to these approaches, highlighting the need to identify metabolic cues in the tumor microenvironment that drive this evasion. Here, we identify lactate as a critical metabolite that mediates detrimental metabolic crosstalk between HCC cells and hepatic stellate cells (HSCs), coupling this interaction to pyrimidine biosynthesis and enhanced extracellular matrix (ECM) production within the tumor microenvironment. We show that tumor-derived lactate activates mechanistic target of rapamycin complex 1 (mTORC1)-carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase (CAD) signaling, enhancing de novo pyrimidine biosynthesis and pre-ribosomal RNA synthesis, thereby promoting ECM protein translation. The resulting ECM deposition drives Yes-associated protein (YAP)/TEA domain family member (TEAD)-dependent upregulation of the cystine/glutamate antiporter (xCT) in HCC cells, conferring marked resistance to sorafenib-induced ferroptosis. Inhibition of dihydroorotate dehydrogenase, the rate-limiting enzyme in pyrimidine synthesis, disrupts ECM production and restores ferroptosis sensitivity in vitro and in vivo. Clinical data further support these findings, indicating that phosphorylated CAD (p-CAD) levels in HSCs are associated with both poor prognosis and lactate-associated ECM enrichment in HCC patients. Collectively, our study identifies lactate-fueled pyrimidine biosynthesis as a key driver of ECM remodeling and ferroptosis resistance in HCC. Targeting this metabolic axis offers a promising therapeutic strategy to overcome ECM-mediated drug resistance and improve outcomes with ferroptosis-based HCC therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.